278 related articles for article (PubMed ID: 29569389)
1. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study).
Morgia G; Vespasiani G; Pareo RM; Voce S; Madonia M; Carini M; Ingrassia A; Terrone C; Gentile M; Carrino M; Giannantoni A; Blefari F; Arnone S; Santelli G; Russo GI;
BJU Int; 2018 Aug; 122(2):317-325. PubMed ID: 29569389
[TBL] [Abstract][Full Text] [Related]
2. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
Morgia G; Russo GI; Voce S; Palmieri F; Gentile M; Giannantoni A; Blefari F; Carini M; Minervini A; Ginepri A; Salvia G; Vespasiani G; Santelli G; Cimino S; Allegro R; Collura Z; Fragalà E; Arnone S; Pareo RM
Prostate; 2014 Nov; 74(15):1471-80. PubMed ID: 25154739
[TBL] [Abstract][Full Text] [Related]
3. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
4. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
[TBL] [Abstract][Full Text] [Related]
7. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
11. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
MacDonald R; Tacklind JW; Rutks I; Wilt TJ
BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
13. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Yoshida M; Origasa H; Seki N
Low Urin Tract Symptoms; 2017 Sep; 9(3):176-186. PubMed ID: 28439987
[TBL] [Abstract][Full Text] [Related]
15. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
16. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Singh I; Tk A; Gupta S
Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
[TBL] [Abstract][Full Text] [Related]
18. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial.
Nagasubramanian S; John NT; Antonisamy B; Mukha RP; Jeyachandra Berry CS; Kumar S; Devasia A; Kekre NS
BJU Int; 2020 May; 125(5):718-724. PubMed ID: 32012409
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
20. Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.
Angalakuditi M; Seifert RF; Hayes RP; O'Leary MP; Viktrup L
Health Qual Life Outcomes; 2010 Nov; 8():131. PubMed ID: 21073697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
